Loading…
Catwalk Cosmetic Laboratories Pty Ltd., a South African OTC drug manufacturer, failed to comply with Current Good Manufacturing Practice (CGMP) regulations, rendering its drug products adulterated. The company did not adequately test incoming components to verify their identity, relying instead on visual inspection of supplier certificates of analysis and informal checks like rancidity assessment. This violation of 21 CFR 211.84(d)(1) represented a significant gap in quality control for finished pharmaceuticals that the FDA identified during its review of records submitted in March 2024.